Biophan Moves to Next Phase of Development with MYO-VAD(TM) Cardiac Support System.

Completion of Device Tooling Enables Pre-Clinical Animal Testing to Commence at Leading Research Sites

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, announced today that the Company is advancing to the next phase of development of the MYO-VAD cardiac support system with co-developer MYOTECH, LLC.

MYOTECH has completed the tooling for the first production device. The device will be used in first quarter 2007 animal tests to verify product performance and prepare for clinical studies in humans. The animal trials will be conducted at four research sites, in cooperation with leaders in the field of cardiac support.

"We are excited to be starting the final stages of animal testing that will precede human clinical trials next year," stated Michael Weiner, CEO of Biophan. "These animal trials at four leading research sites are required to qualify the device for human clinical trials. We believe that the MYO-VAD can change the way many forms of heart failure are treated and once it is approved, it has the potential to save thousands of lives."

Information on the MYO-VAD can be found at www.biophan.com.

About MYOTECH, LLC

MYOTECH, LLC, is a privately-held medical technology development company, formed in 2003 to commercialize a family of medical products based upon Direct Mechanical Ventricular Actuation ("DMVA") cardiac support technology. This technology has permitted the development of minimally invasive heart support devices that promise to provide safer, more effective, and less expensive treatment for patients with many types of heart failure. MYOTECH has relationships with leading physicians and medical institutions who are assisting MYOTECH in the commercialization of its technology. MYOTECH has several pending patents pertaining to the DMVA technology.

About Biophan

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company's technologies, which improve the MRI safety and image compatibility of medical devices, are licensed to leading device manufacturers. In addition, the Company is commercializing the MYOTECH MYO-VAD(TM), a new, cardiac support system which has significant potential to improve the treatment of many forms of heart disease. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.